RxCelerate

RxCelerate is a privately held contract research organization (CRO) founded in 2012 and headquartered in Cambridge, UK. It operates as a specialized drug discovery and development platform, offering end-to-end outsourced services powered by proprietary technologies like its RxNfinity in silico screening, Galaxy antibody discovery, and ProQuant proteomics platforms. The company differentiates itself through a bespoke, toolkit-focused approach to complex biology, aiming to de-risk and accelerate client programs efficiently. Its success-driven model aligns its incentives with those of its biopharma partners, ranging from virtual biotechs to larger organizations.

RxCelerate's integrated platform includes RxNfinity™ for in silico screening, the Galaxy® platform for antibody discovery, ProQuant® for proteomics, and RxPlorer™ for metastate discovery. This toolkit-focused approach enables bespoke drug design for both small molecules and biologics.

RxCelerate competes in the fragmented drug discovery services market against large, full-service CROs (e.g., Charles River, LabCorp) and numerous specialized boutiques. It differentiates through its fully integrated, bespoke platform model, proprietary technologies, and a success-driven, client-aligned business approach focused on complex biology.